Last Price | 9.98 | Max Price | 14.07 |
Min Price | 4.80 | 1 Year return | 2610.00 |
Sector | Health Care | Subsector | Biotechnology |
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 17 | 141,925 | 0.01 % |
2020 | 89 | 170,231 | 0.05 % |
2021 | 2 | 252,886 | 0.00 % |
2022 | 3 | 238,500 | 0.00 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
No Records Found
No Records Found
Verastem Inc's core business is the health care eq. & services sector. The global health care companies gained around 102 percent over the period 2006-2016. Measured since 2011 the sector is 64 percent higher and over the past 12 months (December 2015-December 2016) there is a plus of 102 percent.
Over the last 12 months, that were loss-making period for the investors in Verastem Inc, the stock lost around 36 percent. The period between August 2011 and August 2016 was a loss-making period for the investors. The stock lost on average 0 percent. The net results between 2011 and 2015 were far from constant and fluctuated between -13,68 million dollars and -57,87 million dollars.
The American company didn't pay out any dividends (in the past 5 years).
At the end of 2015 the American company had a balance sheet of 113,09 million dollars. At the end of 2015 the total debt positon equaled 10,62 million dollars. This is around 9,39 percent of the total balance sheet. At the end of 2015 the health care company's stock was traded with a price/earnings-ratio -6. So the stock' value was -6 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.
At the end of 2015 the American company's market capitalization equaled around 66,47 million dollars. At the end of 2015 the American company had around 35,93 million stocks listed on the stock exchange(s).
All Verastem Inc's annual reports can be found here. More information about Verastem Inc can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
0
|
0
|
0
|
27
|
17
|
89
|
Costs |
58
|
36
|
68
|
99
|
167
|
156
|
Profit |
-58
|
-36
|
-68
|
-72
|
-149
|
-68
|
Margin of profit |
0.0
|
0.0
|
0.0
|
-271.07
|
-854.58
|
-76.51
|
ROI |
-56.48
|
-50.40
|
-117.55
|
-58.27
|
-2081.03
|
-58.76
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
102
|
72
|
58
|
124
|
7
|
115
|
Debt |
11
|
11
|
32
|
153
|
138
|
39
|
Total assets |
113
|
84
|
90
|
277
|
145
|
154
|
Solvency |
90.61
|
86.45
|
64.24
|
44.83
|
4.94
|
74.68
|
Cash |
110
|
81
|
87
|
250
|
76
|
141
|
Cashflow |
-46
|
-29
|
-57
|
-75
|
-139
|
-34
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
-4.29
|
-2.60
|
-1.78
|
-0.49
|
-1.00
|
-0.86
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
1.86
|
1.12
|
3.07
|
3.36
|
1.34
|
Eps |
-0.99
|
-1.76
|
-1.12
|
-2.00
|
-0.44
|
Price/earnings-ratio |
-1.88
|
-0.64
|
-2.74
|
-1.68
|
-24.64
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
1.95
|
1.14
|
1.68
|
0.09
|
0.68
|
Market to book |
1.05
|
1.01
|
0.55
|
0.03
|
0.06
|
Cashflow per stock |
-0.80
|
-1.13
|
-1.01
|
-1.73
|
-0.20
|
Stocks |
37
|
51
|
74
|
80
|
170
|
Market Cap |
68.81
|
56.90
|
226.58
|
269.20
|
1.847.74
|
Date
|
Price
|
---|---|
01 May 2024
|
9.98
|
22 Apr 2024
|
10.84
|
18 Apr 2024
|
10.84
|
17 Apr 2024
|
10.93
|
09 Apr 2024
|
11.86
|
05 Apr 2024
|
11.33
|
03 Apr 2024
|
11.52
|
30 Mar 2024
|
11.80
|
22 Mar 2024
|
11.93
|
18 Mar 2024
|
11.00
|
15 Mar 2024
|
10.50
|
12 Mar 2024
|
11.44
|
11 Mar 2024
|
11.57
|
09 Mar 2024
|
11.57
|
07 Mar 2024
|
12.69
|
01 Mar 2024
|
12.46
|
29 Feb 2024
|
12.81
|
27 Feb 2024
|
13.09
|
22 Feb 2024
|
12.33
|
21 Feb 2024
|
12.67
|
20 Feb 2024
|
12.45
|
15 Feb 2024
|
11.86
|
14 Feb 2024
|
11.74
|
13 Feb 2024
|
11.86
|
09 Feb 2024
|
13.45
|
08 Feb 2024
|
13.45
|
07 Feb 2024
|
14.07
|
06 Feb 2024
|
12.30
|
05 Feb 2024
|
12.25
|
01 Feb 2024
|
11.75
|